Prisyna, an oral care unit of biotech firm Synedgen, has received a $6 million equity investment to expand its product line.
Prisyna will use the money for the development, regulatory approval, and marketing of new and current products. The company uses proprietary glycomics technology, natural materials, and polysaccharides to make oral rinses that support oral health.
Prisyna offers two oral rinse products: Synedent oral care and Synedent Plus oral care with fluoride. Products in development include Moistagen, a treatment for dry mouth, and a new formulation to treat the symptoms of oral mucositis caused by chemotherapy or radiation treatments.
A clinical evaluation of Moistagen demonstrated statistically significant reductions in 15 of 33 symptoms associated with dry mouth in 57 patients, the company said. The study was performed at a private practice in Los Angeles and at Tufts University School of Dental Medicine in Boston.
Moistagen is expected to get market clearance from the U.S. Food and Drug Administration in the second half of 2016, the company said.
